Herbal Tonic Fertile Supplement(ZO2C5) ((ZO2C5))

July 11, 2013 updated by: Arash Khaki

Phase 3 of Study on Effects of New Herbal Mixture on Men Infertility

The purpose of this study is to determine whether the effect of mixed herbals drug (citrus, citrolus vol, lan, carrot seed, zingiber, onion, basil, cinnamon) administration on male infertility: oligospermia

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

In the last few years, a marked decrease in the quality of semen has been reported. Infertility is one of the major health problems in 10 to 15% of couples' lives; from which approximately 50% of couple's infertility is due to Male factors. The aim of the present study was to evaluate an herbal mixed effects on spermatogenesis and the normal production of sperm. Researchers have reported that using antioxidants and vitamins A, B, C, E, flavonoids, Sulfur compounds, terpenoids and phenolic compounds in the daily diet can protect sperm. In this study the investigators aimed to assess synergistic effect of these herbal compounds in male Infertility. 700 mg tablet for 180 consequence days/daily will be advising, for 40 patients semen samples in 1th and 180 day after treatment will take, in andrology lab according WHO method:samples put into 2 mL of medium (Hams F10) containing 0.5% bovine serum albumin. After 5 min incubation at 37oC (with 5% CO), the sperm samples were determined using the standard haemocytometric method, and sperm motility was analyzed by microscope (Olympus IX70) at 10 field and reported as the mean of motile sperm according to WHO methods . The sperm abnormality was evaluated according to the standard method of Narayana .Briefly, smears of the sperm suspension were made on clean glass slides and stained with periodic acid-Schiff's reaction haematoxylin. The stained smears were observed under a light microscopic with 40× magnification. The sperms were classified into normal and abnormal. The total sperm abnormality was expressed as percentage incidence. Other biochemical tests will be doing according the our research protocol and thesis for blood samples for measure LH, Testosterone, TAC, Glc and Cholesterol.

Study Type

Interventional

Enrollment (Actual)

1

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Azarbyjan
      • Tabriz, Azarbyjan, Iran, Islamic Republic of, 51388
        • Womens Reproductive Health Research Center,Tabriz University Of Medical Sciences,Iran

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

25 years to 50 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • all patients suffering from oligospermia are included

Exclusion Criteria:

  • any diseases

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: fertility coated tablet
700 mg fertility coated tablet containing 8 herbal powders by mouth every 12 hours for 180 days
this supplement contains 700 mg of 8 natural herbals: Citrus & ZINGIBER OFFICINALE & Onion & Ocimum basilicum & Cinnamomum zelanicum & Citrullus lanatus & Citrullus vulgaris & Daucus carota
Other Names:
  • Dietry supplement

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Sperm count variation
Time Frame: First day of research, 2th time for sampling is 180 days after treatment
Semen analysis according WHO methods
First day of research, 2th time for sampling is 180 days after treatment

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Sperm motility
Time Frame: 1th time in first day of research, 2th time after 180 days of treatment
Semen analysis
1th time in first day of research, 2th time after 180 days of treatment
Sperm Viability
Time Frame: 1th time in first day of research, 2th time after 180 days of treatment
Semen analysis
1th time in first day of research, 2th time after 180 days of treatment

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Testosterone levels
Time Frame: 1th time in first day of research, 2th time after 180 days of treatment
Testosterone analysis
1th time in first day of research, 2th time after 180 days of treatment
Serum Total antioxidant levels
Time Frame: 1th time in first day of research, 2th time after 180 days of treatment
Total antioxidant measurement in serum
1th time in first day of research, 2th time after 180 days of treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Director: Arash Khaki, PhD, Women Reproductive Health Research Center,Tabriz University of medical Sciences

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2012

Primary Completion (Actual)

June 1, 2012

Study Completion (Actual)

June 1, 2012

Study Registration Dates

First Submitted

September 12, 2012

First Submitted That Met QC Criteria

July 7, 2013

First Posted (Estimate)

July 11, 2013

Study Record Updates

Last Update Posted (Estimate)

July 12, 2013

Last Update Submitted That Met QC Criteria

July 11, 2013

Last Verified

July 1, 2013

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • WRHRC-9026

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Male Infertility

Clinical Trials on coated tablet

Subscribe